Cyclosporine-sparing effects of daclizumab in renal allograft recipients-Reference-Cited by-同舟云学术

Cyclosporine-sparing effects of daclizumab in renal allograft recipients

Published:2005-02-15 Issue:4 Volume:62 Page:391-396
ISSN:1079-2082
Container-title:American Journal of Health-System Pharmacy
language:en
Short-container-title:

Author:

Ingle Gordon R.¹,Moudgil Asha²,Vo Ashley,Jordan Stanley C.³

Affiliation:

1. Department of Pharmacy, St. Vincent Medical Center, Los Angeles, CA, and Assistant Clinical Professor, School of Pharmacy, University of Southern Nevada, Henderson

2. Department of Nephrology, Children’s National Medical Center, Washington, DC

3. Renal Transplantation and Transplant Immunology, Department of Renal Transplantation and Transplant Immunology, Cedars-Sinai Health System

Publisher

Oxford University Press (OUP)

Subject

Health Policy,Pharmacology

Link

http://academic.oup.com/ajhp/article-pdf/62/4/391/28322614/ajhp0391.pdf

Reference19 articles.

1. PROGRESSION OF KIDNEY DISEASE IN CHRONIC RENAL TRANSPLANT REJECTION

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study;Nephrology Dialysis Transplantation;2010-01-26

2. Extended daclizumab monotherapy for rejection-free survival in non-adherent adolescent recipients of renal allografts;Pediatric Transplantation;2009-11

3. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation;Nephrology Dialysis Transplantation;2009-09-22

4. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group;Annals of the Rheumatic Diseases;2008-10-01

5. Lifespan Analysis of 212 Transplanted Kidney Grafts: Effects of Use of Humanized Anti–IL-2R Monoclonal Antibody in Graft Survival at 1, 3, and 5 Years for 108 Recipients;Transplantation Proceedings;2007-10